Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.

NCT00275665 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00275665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00275665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.
Lead sponsor
Mayo Clinic
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2001
Completion date
July 31, 2007
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow stem cell transplant